Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-03-11 Legal Proceedings Report
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(증권선물위원회 조사ㆍ감리 결과)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure regarding the results of an investigation and audit by the Securities and Futures Commission (SFC) into Celltrion Pharm. It details specific accounting violations, penalties (fines, auditor designation, internal control improvements), and management's response. Since this is a formal regulatory announcement regarding legal/compliance proceedings and regulatory actions, it fits best under 'Legal Proceedings Report' (LTR) as it concerns regulatory enforcement actions and legal compliance outcomes.
2022-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Celltrion Pharm. It contains the meeting agenda, details on voting procedures (including electronic voting), and management reference materials such as financial statements and director activity reports. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming AGM, which falls under the Proxy Solicitation & Information Statement category.
2022-03-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used to provide shareholders with information regarding upcoming general meetings, including agenda items, director nominations, and financial summaries, to solicit their votes. This falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-08 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal notification filed by Celltrion Pharm regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling and mentions the company's compliance efforts regarding shareholder participation. Since this is a regulatory disclosure regarding the logistics of a shareholder meeting rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2022-03-08 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Celltrion Pharm titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and auditor information. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report document (AR). In the context of Korean regulatory filings (DART/KIND), this specific format is a standard disclosure announcement regarding the submission of the audit report. Given the 'Menu vs Meal' rule and the nature of the disclosure, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-08 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Celltrion Pharm, Inc. covering the fiscal year 2021 (Jan 1, 2021 to Dec 31, 2021). It contains comprehensive financial data, business operations, management discussions, and governance details, which aligns with the definition of an Annual Report (10-K). FY 2021
2022-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.